Table 4.
Clinical characteristics of patients with AML1::ETO and KIT exon 17 mutation and without AML1::ETO nor KIT mutation in TARGET
| Total | AML1::ETO and KIT exon 17 mutation | Without AML1::ETO nor 17 KIT mutation | P value | |
|---|---|---|---|---|
| Patients, n(%) | 96 | 15 | 81 | |
| Demographics | ||||
| Gender | 0.99 | |||
| Male | 46.9% (45/96) | 46.7% (7/15) | 46.9% (38/81) | |
| Female | 53.1% (51/96) | 53.3% (8/15) | 53.1% (43/81) | |
| Race | 0.001** | |||
| Asian | 2.1% (2/96) | 6.7% (1/15) | 1.2% (1/81) | |
| Black or African | 8.3% (8/96) | 0.0% (0/15) | 9.9% (8/81) | |
| White | 72.9% (70/96) | 46.7% (7/15) | 77.8% (63/81) | |
| Other | 9.4% (9/96) | 13.3% (2/15) | 8.7% (7/81) | |
| Unknown | 6.3% (6/96) | 33.3% (5/15) | 1.2% (1/81) | |
| American Indian or Alaska Native | 1.0% (1/96) | 0.0% (0/15) | 1.2% (1/81) | |
| Ethnicity | 0.01* | |||
| Hispanic or Latino | 26.1% (25/96) | 53.3% (8/15) | 21.0% (17/81) | |
| Not Hispanic or Latino | 70.8% (68/96) | 40.0% (6/15) | 76.5% (62/81) | |
| Unknown | 3.1% (3/96) | 6.7% (1/15) | 2.5% (2/81) | |
| Age(years) | 0.78 | |||
| < 10 | 39.6% (38/96) | 33.3% (5/15) | 40.7% (33/81) | |
| ≥ 10 | 60.4% (58/96) | 66.7% (10/15) | 59.3% (48/81) | |
| Risk group | 1.00 | |||
| High | 2.1% (2/96) | 0.0% (0/15) | 2.5% (2/81) | |
| Standard | 2.1% (2/96) | 0.0% (0/15) | 2.5% (2/81) | |
| Low | 95.8% (92/96) | 100.0% (15/15) | 95.0% (77/81) | |
| Clinical features | ||||
| Treatment protocol | 0.66 | |||
| AAML03P1 | 7.3% (7/96) | 0.0% (0/15) | 8.6% (7/81) | |
| AAML0531 | 87.5% (84/96) | 93.3% (14/15) | 86.4% (70/81) | |
| CCG-2961 | 5.2% (5/96) | 6.7% (1/15) | 5.0% (4/81) | |
| Initial WBC count(10^9/L) | 0.004** | |||
| < 50 | 39.6% (38/96) | 73.3% (11/15) | 33.3% (27/81) | |
| ≥ 50 | 60.4% (58/96) | 26.7% (4/15) | 66.7% (54/81) | |
| FAB Category | < 0.001*** | |||
| M1 | 3.1% (3/96) | 13.3% (2/15) | 1.2% (1/81) | |
| M2 | 12.5% (12/96) | 73.4% (11/15) | 1.2% (1/81) | |
| M4 | 73.0 % (70/96) | 0.0% (0/15) | 86.5% (70/81) | |
| M5 | 1.0% (1/96) | 0.0% (0/15) | 1.2% (1/81) | |
| NOS | 1.0% (1/96) | 0.0% (0/15) | 1.2% (1/81) | |
| Unknown | 9.4% (9/96) | 13.3% (2/15) | 8.7% (7/81) | |
| Therapeutic evaluation | ||||
| Course 1 | ||||
| Bone marrow | 0.38 | |||
| CR | 84.2% (80/95) | 73.3% (11/15) | 86.2% (69/80) | |
| Not CR | 15.8% (15/95) | 26.7% (4/15) | 13.8% (11/80) | |
| MRD | 0.52 | |||
| Yes | 13.6% (11/81) | 23.1% (3/13) | 11.8% (8/68) | |
| No | 86.4% (70/81) | 76.9% (10/13) | 88.2% (60/68) | |
| Course 2 | ||||
| Bone marrow | 1.00 | |||
| CR | 93.6% (88/94) | 93.3% (14/15) | 93.7% (74/79) | |
| Not CR | 6.4% (6/94) | 6.7% (1/15) | 6.3% (5/79) | |
| MRD | 1.00 | |||
| Yes | 6.0% (4/67) | 9.1% (1/11) | 5.4% (3/56) | |
| No | 94.0% (63/67) | 90.9% (10/11) | 94.6% (53/56) | |
| GO treatment | 0.34 | |||
| Yes | 54.9% (50/91) | 42.9% (6/14) | 57.1% (44/77) | |
| No | 45.1% (41/91) | 57.1% (8/14) | 42.9% (33/77) | |
| Relapse/Induction Failure | ||||
| Bone Marrow Site of Relapse/Induction Failure | 85.7% (30/35) | 85.7% (6/7) | 85.7% (24/28) | 1.00 |
| CNS Site of Relapse/Induction Failure | 34.3% (12/35) | 28.6% (2/7) | 35.7% (10/28) | 1.00 |
| Chloroma Site of Relapse/Induction Failure | 5.7% (2/35) | 14.3% (1/7) | 3.6% (1/28) | 0.86 |
| Cytogenetic Site of Relapse/Induction Failure | 14.3% (5/35) | 0.0% (0/7) | 17.9% (5/28) | 0.56 |
| Other Site of Relapse/Induction Failure | 5.7% (2/35) | 0.0% (0/7) | 7.1% (2/28) | 1.00 |
P values were analyzed by the Chi-Square Test, compared with AML1::ETO and KIT mutation group
CR Complete remission, MRD Minimal residual disease, WBC White blood cell, GO gemtuzumab ozogamicin
* P < 0.05
** P < 0.01
*** P < 0.001